Tocilizumab for severe COVID‐19 in solid organ transplant recipients: a matched cohort study

The safety and efficacy of tocilizumab for the treatment of severe respiratory symptoms due to COVID‐19 remain uncertain, in particular among solid organ transplant (SOT) recipients. Thus, we evaluated the clinical characteristics and outcomes of 29 hospitalized SOT recipients who received tocilizum...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of transplantation 2020-11, Vol.20 (11), p.3198-3205
Hauptverfasser:	Pereira, Marcus R., Aversa, Meghan M., Farr, Maryjane A., Miko, Benjamin A., Aaron, Justin G., Mohan, Sumit, Cohen, David J., Husain, Syed A., Ratner, Lloyd E., Arcasoy, Selim, Uriel, Nir, Zheng, Elizabeth X., Fox, Alyson N., Tsapepas, Demetra S., Emond, Jean C., Verna, Elizabeth C.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antibodies, Monoclonal, Humanized - therapeutic use Brief Communication Brief Communications clinical research/practice Cohort analysis Comorbidity complication: infectious Corticosteroids COVID-19 COVID-19 - epidemiology Female Graft Rejection - epidemiology Graft Rejection - prevention & control Humans immune regulation immunosuppression/immune modulation Immunosuppressive agents infectious disease Kidney diseases Male Medical treatment Middle Aged Monoclonal antibodies Mortality Organ Transplantation Pandemics Patients SARS-CoV-2 Transplant Recipients
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!